GLP-1 Dosing and Titration Protocols: A Clinical Reference

Proper dosing and titration is one of the most important factors in GLP-1 therapy outcomes. Too fast a titration leads to intolerable GI side effects and patient dropout. Too slow a titration delays therapeutic benefit. Getting it right requires understanding the pharmacology and having a systematic approach.

This post is a clinical reference for prescribers developing GLP-1 dosing and titration protocols.

GLP-1 receptor agonists work in part by slowing gastric emptying and reducing appetite. These same mechanisms produce the most common side effects: nausea, vomiting, diarrhea, and constipation. The severity of these side effects is dose-dependent and tends to diminish over time as patients adapt.

Titration — starting at a low dose and gradually increasing — allows patients to adapt to the medication before reaching therapeutic doses. This dramatically improves tolerability and reduces dropout.

The goal of titration is to reach the dose that produces adequate weight loss with acceptable tolerability for each individual patient. This is not always the maximum dose — some patients achieve excellent results at lower doses.

Common concentrations for compounded semaglutide:

• 2.5 mg/mL (0.1 mL = 0.25 mg)
• 5 mg/mL (0.1 mL = 0.5 mg)
• 10 mg/mL (0.1 mL = 1.0 mg)

• If GI side effects are intolerable, hold the current dose for an additional 4 weeks before increasing
• If a patient misses doses for more than 2 weeks, consider restarting at a lower dose
• Some patients achieve adequate response at lower doses and do not need to reach 2.4 mg

Common concentrations:

• 2.5 mg/mL (1 mL = 2.5 mg)
• 5 mg/mL (1 mL = 5 mg)
• 10 mg/mL (1 mL = 10 mg)

• Tirzepatide tends to be better tolerated than semaglutide at equivalent weight loss doses
• The 4-week titration intervals can be extended to 8 weeks if needed for tolerability
• Many patients achieve excellent results at 5–10 mg and do not need to reach 15 mg

Retatrutide is not FDA-approved, and there is no established standard titration protocol. The Phase 2 trial used the following schedule:

• The glucagon receptor agonism component may produce more pronounced GI effects than semaglutide or tirzepatide
• Slower titration may be appropriate for patients with a history of GI intolerance to other GLP-1 agents
• Monitor heart rate — glucagon receptor agonism can increase heart rate
• Blood glucose monitoring may be appropriate, particularly in patients with diabetes or prediabetes

• Most common side effect; typically peaks 1–3 days after injection
• Advise patients to eat smaller meals, avoid high-fat foods, and eat slowly
• Ginger tea or ginger supplements may help
• If severe, consider anti-nausea medication (ondansetron, promethazine)

• Less common than nausea; usually resolves with dose stabilization
• Ensure adequate hydration
• If persistent, hold dose escalation

• Common early in treatment; usually self-limiting
• Advise adequate hydration
• Loperamide can be used for symptomatic relief

• Less common than diarrhea but can occur
• Adequate hydration and fiber intake
• Stool softeners if needed

• Rotate injection sites
• Allow medication to reach room temperature before injection
• Inject slowly

Recommended monitoring:

• Weight at each visit
• Blood pressure
• Heart rate (particularly with retatrutide)
• HbA1c (for patients with diabetes or prediabetes)
• Lipid panel (annually or as indicated)
• Kidney function (GLP-1 agents can affect kidney function in some patients)

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should use clinical judgment and review current literature when developing patient protocols.